Akribion Therapeutics
Akribion Therapeutics is developing a unique, RNA-guided, nuclease-based technology for programmable cell depletion. Their proprietary G-dase® E nucleases allow for the specific depletion of targeted cells, leaving healthy cells unharmed. This technology has potential applications in oncology, autoimmune diseases, fibrosis, and infectious diseases.
Funding Round: Seed
Funding Amount: €8M
Date: 04-Feb-2025
Investors: CARMA FUND, RV Invest, MP Beteiligungs GmbH, Hessen Kapital I, Bruker Invest, High-Tech Gründerfonds
Markets: Biotechnology, Oncology, Autoimmune Diseases, Fibrosis, Infectious Diseases, CRISPR, Therapeutics
HQ: Zwingenberg, Hesse, Germany
Founded: 2023
Website: https://www.akribion-therapeutics.com/
LinkedIn: https://www.linkedin.com/company/akribion-therapeutics
Leave a Comment
Comments
No comments yet.